Development of resistance mutations to nevirapine as part of triple-drug therapy in children.
Five children received nevirapine, a nonnucleoside reverse transcriptase inhibitor used as part of a triple-drug regimen to treat human immunodeficiency virus infection. They all developed resistance mutations to the agent within 4-10 months. They differed in compliance with drug therapy and development of specific mutations. Whether these mutations predict clinical resistance has yet to be determined.
Seifert
Lynn L
LL
Pharmacy Department, University of California Davis Medical Center, Sacramento 95831, USA.
D000293:Adolescent; D023241:Antiretroviral Therapy, Highly Active; D002648:Child; D002675:Child, Preschool; D024882:Drug Resistance, Viral / Q000235:genetics*; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000235:genetics* / Q000821:virology; D054303:HIV Reverse Transcriptase / Q000037:antagonists & inhibitors / Q000235:genetics; D015497:HIV-1 / Q000235:genetics; D006801:Humans; D008297:Male; D009154:Mutation / Q000235:genetics*; D019829:Nevirapine / Q000627:therapeutic use*; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*
D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; D054303:HIV Reverse Transcriptase